A carregar...
PPMS onset upon adalimumab treatment extends the spectrum of anti-TNF-α therapy-associated demyelinating disorders
Since their introduction in 1999, anti-tumour necrosis factor-α (anti-TNF-α) therapies have been suspected repeatedly to be associated with the occurrence of central nervous system (CNS) demyelinating disorders, including multiple sclerosis (MS). However, recent publications were restricted to descr...
Na minha lista:
| Publicado no: | Ther Adv Neurol Disord |
|---|---|
| Main Authors: | , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
SAGE Publications
2020
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6940603/ https://ncbi.nlm.nih.gov/pubmed/31921355 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/1756286419895155 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|